Benefits and challenges of antibody drug conjugates as novel form of chemotherapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Benefits and challenges of antibody drug conjugates as novel form of chemotherapy
Authors
Keywords
Antibody drug conjugate, Cancer therapy, Payload, Linker, Targeted drug delivery, Antibody conjugated nanoparticles
Journal
JOURNAL OF CONTROLLED RELEASE
Volume 341, Issue -, Pages 555-565
Publisher
Elsevier BV
Online
2021-12-11
DOI
10.1016/j.jconrel.2021.12.013
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Functional Choline Phosphate Lipids for Enhanced Drug Delivery in Cancer Therapy
- (2021) Wenliang Wang et al. CHEMISTRY OF MATERIALS
- Nanotechnology for Modern Medicine: Next Steps Towards Clinical Translation
- (2021) Shrey Sindhwani et al. JOURNAL OF INTERNAL MEDICINE
- Impact of Drug Conjugation and Loading on Target Antigen Binding and Cytotoxicity in Cysteine Antibody–Drug Conjugates
- (2021) Durgesh V. Nadkarni et al. MOLECULAR PHARMACEUTICS
- Overcoming barriers by local drug delivery with liposomes
- (2021) S.G. Antimisiaris et al. ADVANCED DRUG DELIVERY REVIEWS
- Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody–Drug Conjugates
- (2021) Stepan Chuprakov et al. BIOCONJUGATE CHEMISTRY
- What makes a good antibody–drug conjugate?
- (2021) Martin De Cecco et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Unlocking the potential of antibody–drug conjugates for cancer therapy
- (2021) Joshua Z. Drago et al. Nature Reviews Clinical Oncology
- The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials
- (2021) Martin Snajdauf et al. Frontiers in Molecular Biosciences
- Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect
- (2021) Aleksandr V. Yurkovetskiy et al. MOLECULAR CANCER THERAPEUTICS
- Microfluidics-assisted conjugation of chitosan-coated polymeric nanoparticles with antibodies: Significance in drug release, uptake, and cytotoxicity in breast cancer cells
- (2021) Noé Escareño et al. JOURNAL OF COLLOID AND INTERFACE SCIENCE
- In vivo safety testing of Antibody Drug Conjugates
- (2021) Francesca Pretto et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
- (2021) Juliana T. W. Tong et al. MOLECULES
- Site-specific conjugation of native antibodies using engineered microbial transglutaminases
- (2020) Stephan Dickgiesser et al. BIOCONJUGATE CHEMISTRY
- Emergence in protein derived nanomedicine as anticancer therapeutics: More than a tour de force
- (2020) Zhenchang Wang et al. SEMINARS IN CANCER BIOLOGY
- Therapeutic Nanoparticles and Their Targeted Delivery Applications
- (2020) Abuzer Alp Yetisgin et al. MOLECULES
- Recent advances of antibody drug conjugates for clinical applications
- (2020) Pengxuan Zhao et al. Acta Pharmaceutica Sinica B
- Nanoparticle-Based Drug Delivery System: A Patient-Friendly Chemotherapy for Oncology
- (2020) Lina Yan et al. Dose-Response
- Antibody-Drug Conjugates: The New Frontier of Chemotherapy
- (2020) Sara Ponziani et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Recent trends in protein and peptide-based biomaterials for advanced drug delivery
- (2020) Anastasia Varanko et al. ADVANCED DRUG DELIVERY REVIEWS
- Antibody–Drug Conjugates: The Last Decade
- (2020) Nicolas Joubert et al. Pharmaceuticals
- Safety and Tolerability of Antibody-Drug Conjugates in Cancer
- (2019) Anna Wolska-Washer et al. DRUG SAFETY
- Gemtuzumab ozogamicin in acute myeloid leukemia: act 2, with perhaps more to come
- (2019) Johann Hitzler et al. HAEMATOLOGICA
- Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
- (2019) Prathap Kumar Mahalingaiah et al. PHARMACOLOGY & THERAPEUTICS
- The Analysis of Key Factors Related to ADCs Structural Design
- (2019) Haichao Tang et al. Frontiers in Pharmacology
- Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy
- (2019) Sajad Yaghoubi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Site-specific bioconjugation and self-assembly technologies for multi-functional biologics: on the road to the clinic
- (2019) Sung In Lim DRUG DISCOVERY TODAY
- Antibody-Drug Conjugates: A Comprehensive Review
- (2019) Puregmaa Khongorzul et al. MOLECULAR CANCER RESEARCH
- Antibodies to watch in 2020
- (2019) Hélène Kaplon et al. mAbs
- Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma
- (2018) Tessa Gargett et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Fate of Antibody-Drug Conjugates in Cancer Cells
- (2018) Cécile Chalouni et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33‐Positive Acute Myeloid Leukemia
- (2018) Kelly J. Norsworthy et al. ONCOLOGIST
- Forming next-generation antibody–nanoparticle conjugates through the oriented installation of non-engineered antibody fragments
- (2018) Michelle K. Greene et al. Chemical Science
- Highly Potent, Anthracycline-based Antibody–Drug Conjugates Generated by Enzymatic, Site-specific Conjugation
- (2017) Nikolas Stefan et al. MOLECULAR CANCER THERAPEUTICS
- Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy
- (2017) Hao Chen et al. MOLECULES
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- Antibody fragments as nanoparticle targeting ligands: a step in the right direction
- (2017) Daniel A. Richards et al. Chemical Science
- T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity
- (2017) Daniela Schmid et al. Nature Communications
- Antibody drug conjugates: lessons from 20 years of clinical experience
- (2016) A. W. Tolcher ANNALS OF ONCOLOGY
- Antibody-drug conjugates—an emerging class of cancer treatment
- (2016) Nikolaos Diamantis et al. BRITISH JOURNAL OF CANCER
- Towards the next generation of biomedicines by site-selective conjugation
- (2016) Qi-Ying Hu et al. CHEMICAL SOCIETY REVIEWS
- Linkers Having a Crucial Role in Antibody–Drug Conjugates
- (2016) Jun Lu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Current Status: Site-Specific Antibody Drug Conjugates
- (2016) Dominik Schumacher et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Antibody–drug conjugates for cancer therapy
- (2016) Anish Thomas et al. LANCET ONCOLOGY
- Antibody-drug conjugates: Current status and future perspectives
- (2016) Rémy Gébleux et al. PHARMACOLOGY & THERAPEUTICS
- Onivyde for the therapy of multiple solid tumors
- (2016) Haijun Zhang OncoTargets and Therapy
- Antibody-drug conjugates: recent advances in conjugation and linker chemistries
- (2016) Kyoji Tsuchikama et al. Protein & Cell
- Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development
- (2015) Paresh Agarwal et al. BIOCONJUGATE CHEMISTRY
- CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses
- (2015) Rodney A. Rosalia et al. BIOMATERIALS
- Current methods for the synthesis of homogeneous antibody–drug conjugates
- (2015) Alicja M. Sochaj et al. BIOTECHNOLOGY ADVANCES
- Emerging formats for next-generation antibody drug conjugates
- (2015) Mahendra P Deonarain et al. Expert Opinion on Drug Discovery
- Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy
- (2014) Ravi V. J. Chari et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- The Next Generation of Antibody Drug Conjugates
- (2014) Fiona Mack et al. SEMINARS IN ONCOLOGY
- Antibody–drug conjugates: Basic concepts, examples and future perspectives
- (2012) Giulio Casi et al. JOURNAL OF CONTROLLED RELEASE
- Antibody-targeted nanoparticles for cancer therapy
- (2011) Francois Fay et al. Immunotherapy
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started